- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02642718
Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy
Background: Experimental models using short duration noxious stimuli have led to the concept of pre-emptive analgesia. Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), has been shown to have a post-operative narcotic sparing effect when given pre-operatively and alternatively to not have this effect. This study was undertaken to determine whether a single intravenous dose of ketorolac would result in decreased post-operative pain and narcotic requirements.
Methods: In a double-blind, randomized controlled trial, 48 women undergoing abdominal hysterectomy were studied. Patients in the ketorolac group received 30 mg of intravenous ketorolac 30 minutes before surgical incision, while the control group received normal saline. The post-operative analgesia was performed with a continuous infusion of tramadol at 12 mg/hour with the possibility of a 10 mg bolus every 10 minutes. Pain was assessed using the Visual Analog Scale (VAS), tramadol consumption and hemodynamic parameters at 0, 1, 2, 4, 8, 12, 16 and 24 hours post-operatively. We quantified times to rescue analgesic (morphine), adverse effects and patient satisfaction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Damage to tissues has been shown to provoke a magnified reaction to noxious stimuli, peripherally by diminishing the threshold of nociceptive afferent nerve terminals and centrally by augmenting the excitability of second-order sensory neurons in the spinal cord; later resulting in an amplification and extension of postoperative pain after surgery. Hence, much research has focused on procedures to avoid these central neuroplastic changes through the usage of preemptive analgesia.
Experimental models have conducted to the idea of 'preemptive analgesia' . The decrement of afferent nociceptive inputs to the spinal cord using analgesic techniques started before the initial painful stimulus avoids or attenuates the formation of spinal hyperexcitabilty and avoids the transformed processing of afferent input, leading to less postoperative pain. Whether such experimental models are applicable to the noxious circumstances occurring during surgery is controversial.
Although preemptive analgesia with different agents have been successful in experimental animals, conclusions from human studies remain in conflict. A diversity of agents have been analyzed for their conceivable preemptive analgesic effects: local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, opioids, magnesium, cytokine synthesis inhibitors, ketamine, and tricyclic antidepressants.
Scientific research enabling an understanding of the molecular mechanisms of nociception has disclosed a considerable function of cytokines and prostaglandins (PG). Hyperexcitability also appears peripherally in nerve endings at the location of surgical tissue damage and is mediated in part by prostaglandins. Evidence is accumulating that products of the cyclooxygenase pathway may be engaged in the elaboration of central sensitization. Drugs that block the formation of prostaglandins such as NSAIDs might therefore be assumed to avoid or minimize the formation of this peripheral and central hyperexcitability. Their central analgesic actions are effected by averting spinal prostaglandin synthesis and attenuating liberation of neurotransmitters from the primary afferent terminals and spinal interneurons.
Sporadic studies have established some considerable preemptive benefit of NSAIDs. As a result, the objective of this study was to ascertain the impact of a NSAID, ketorolac, on pain severity and analgesic requirement, in the early postoperative period.
Ketorolac is a nonselective NSAID that blocks cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) enzymes and as a result blocks the formation of prostaglandins attenuating the sensitization procedures. The antinociceptive and anti-inflammatory action of NSAIDs may be associated to the suppression of nitric oxide synthase activation, decreased generation of proinflammatory cytokines, and lipoxine activation. Consequently, this multidirectional activity indicates that there may be the probability of adjusting the nociception process by the employment of these drugs perioperatively.
To our knowledge, no prior controlled study has determined the effectiveness of preoperative intravenous ketorolac compared to placebo in patients who underwent abdominal hysterectomies. Thus, this clinical trial was conceived to explore the postoperative analgesic efficiency and opioid-sparing action of a single dose of intravenous ketorolac in contrast with placebo administered preoperatively.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
A Coruña
-
Ferrol, A Coruña, Spain, 15405
- Complexo Hospitalario Arquitecto Marcide-Prof. Novoa Santos
-
-
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 9DU
- Oxford University Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- normal height and weight
- ASA class I, II, III
- elective surgery
- surgery time between 30-150 min
- understanding of the Visual Analog Scale (VAS)
- no allergies or intolerance to NSAIDs or anesthetics
- no psychiatric illness.
Exclusion Criteria:
- renal deterioration
- history of peptic ulceration
- asthma
- coagulopathy
- cognitive impairment
- inability to use the Patient Controlled Analgesia (PCA) device
- history of chronic pain syndromes
- history of chronic use of analgesics, sedatives, opioids or steroids
- liver or hematologic disease
- a history of drug or alcohol abuse
- therapy with NSAIDs, anticoagulants, or lithium.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
|
In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
|
Experimental: Ketorolac Tromethamine
In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision.
(a single dose).
|
In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 0 hours postoperatively (arrival at recovery room)
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 0 hours postoperatively (arrival at recovery room)
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 1 hour postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 1 hour postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 2 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 2 hours postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 4 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 4 hours postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 8 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 8 hours postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 12 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 12 hours postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 16 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 16 hours postoperatively
|
Pain as measured by the Visual Analog Scale (VAS) score
Time Frame: at 24 hours postoperatively
|
The VAS represents a scale with the lowest value as 0 (no pain) and the highest value as 10 (worst imaginable pain).
|
at 24 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tramadol consumption
Time Frame: at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
The cumulative amounts of tramadol (mg) administered through the Patient-Controlled-Analgesia (PCA) device as a basal infusion and the incremental supplemental bolus required by the patient were documented at these time points.
|
at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure (BP) systolic
Time Frame: at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Measured in mm Hg.
We evaluated these hemodynamic parameters as an indirect measure of pain.
|
at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Blood Pressure (BP) diastolic
Time Frame: at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Measured in mm Hg.
We evaluated these hemodynamic parameters as an indirect measure of pain
|
at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Time for the first demand of analgesia
Time Frame: 24 h postoperatively.
|
The time interval to first solicited rescue analgesia in the 24 h postoperatively (in minutes).
This rescue analgesia was administered if the established analgesic treatment was not sufficient to alleviate pain.
|
24 h postoperatively.
|
Number of rescue doses
Time Frame: 24 h postoperatively
|
The number of times a rescue analgesic dose was administered as a supplement in the first postoperative 24 hours.
|
24 h postoperatively
|
Satisfaction score
Time Frame: 24 hours postoperatively
|
Global patient satisfaction (0-3), regarding pain control, was measured 24 hours after the operation
|
24 hours postoperatively
|
Side effects
Time Frame: 24 hours postoperatively
|
Number of Participants with Serious and Non-Serious Adverse Events in the 24 hours postoperatively
|
24 hours postoperatively
|
Heart rate
Time Frame: at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
We evaluated these hemodynamic parameters as an indirect measure of pain
|
at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Respiratory rate
Time Frame: at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
We evaluated these hemodynamic parameters as an indirect measure of pain.
|
at 0, 1, 2, 4, 8, 12, 16, and 24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Beatriz Nistal-Nuño, MD, Oxford University Hospitals NHS Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketorolac
- Ketorolac Tromethamine
Other Study ID Numbers
- KP 359352
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States